PPI Sequencing Study

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Esomeprazole; Proton Pump Inhibitors

Criteria

Inclusion Criteria:

• Persisting symptoms of GORD despite previous treatment with a full dose proton pump inhibitor

• Informed consent

• Over 18 years of age

Exclusion Criteria:

• Current course of Proton Pump inhibitor treatment for more than 8 weeks prior to enrolment in the study;

• More than 1 other course of PPI treatment in the previous 12 month;

• Previous use of esomeprazole;

• Presence of alarm symptoms.